Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Chia-Kai Chu

Ophthalmology Houston, TX Medical Doctor

NPI 1356684674 CMS profile 3428423

2855 Gramercy St, Houston, TX 77025

Open in the dashboard

General payments

$4,397

155 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Research they led as principal investigator

$10,154 paid to institutions, not to them · program year 2020

Through program year 2025, Chia-Kai Chu of Houston, TX is reported in the CMS Open Payments database as having received $4,397 across 155 general payments and $0 in research payments paid to them. Separately, studies naming them as principal investigator received $10,154 in research payments, paid to institutions rather than to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them. The principal-investigator line is research money paid to institutions for studies they led — not to them — and is not added to anything either.

General payments for this record sit in the 78th percentile of Ophthalmology profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $785 44
2024 General $710 27
2023 General $442 21
2022 General $546 20
2021 General $1,250 25
2020 General $181 9
2019 General $483 9

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Chia-Kai Chu
  • Ophthalmology median
  • Middle half of Ophthalmology
  • National median

In program year 2025, general payments to Chia-Kai Chu were reported at $785. Among 13,034 Ophthalmology profiles paid that year, the median was $384 and the middle half received between $136 and $917.

Show as a table
Year Chia-Kai Chu Ophthalmology median Middle half National median
2019 $483 $258 $104–$655 $163
2020 $181 $126 $45–$321 $114
2021 $1,250 $205 $76–$534 $132
2022 $546 $266 $100–$678 $149
2023 $442 $308 $117–$745 $160
2024 $710 $340 $127–$846 $164
2025 $785 $384 $136–$917 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. AbbVie, Inc. $1,028 47 payments
  2. Allergan Inc. $892 13 payments
  3. Alcon Vision LLC $762 31 payments
  4. Aerie Pharmaceuticals, Inc. $356 7 payments
  5. Bausch & Lomb Americas Inc. $339 18 payments
  6. Mentor Worldwide LLC $284 2 payments
  7. Bausch & Lomb, a division of Bausch Health US, LLC $178 9 payments
  8. Novartis Pharmaceuticals Corporation $145 7 payments
  9. Thea Pharma Inc. $99 5 payments
  10. Akorn Operating Company LLC $56 3 payments
  11. Other $258 13 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Food and Beverage $3,697 154 payments
  2. Consulting Fee $700 1 payment
Products named General payments · program years 2019–2025
  1. DURYSTA $875 4 payments
  2. LUMIGAN $590 28 payments
  3. VYZULTA $376 19 payments
  4. ALPHAGAN P $304 13 payments
  5. MENTOR MemoryGel Resterilizable Gel Sizer $284 2 payments
  6. Rhopressa Glaucoma $247 2 payments
  7. Rocklatan Glaucoma $247 2 payments
  8. Rocklatan Ophthalmology $223 17 payments
  9. rhopressa Glaucoma $155 7 payments
  10. rocklatan Glaucoma $155 7 payments
  11. Other $1,888 90 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 37 drugs

Part D claims

6,648

Median for Ophthalmology: 891

Drug cost

$941,684

Median for Ophthalmology: $68,233

Branded share of claims

41.8%

Median for Ophthalmology: 29.7%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Lumigan Bimatoprost Brand 318 $177,808
Combigan Brimonidine Tartrate/Timolol Brand 262 $119,170
Restasis Cyclosporine Brand 117 $113,057
Rhopressa Netarsudil Mesylate Brand 212 $100,755
Vyzulta Latanoprostene Bunod Brand 106 $53,904
Alphagan P Brimonidine Tartrate Brand 94 $36,387
Rocklatan Netarsudil Mesylat/Latanoprost Brand 78 $32,378
Brimonidine Tartrate-Timolol Brimonidine Tartrate/Timolol Brand 129 $26,928
Tyrvaya Varenicline Tartrate Brand 20 $25,243
Brimonidine Tartrate Generic 441 $22,244

The 10 drugs with the highest cost, of 37 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 18,260 Part D prescribers listed as Ophthalmology; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 29 billing codes

Paid by Medicare

$179,508

Medicare's payments for the services billed

Medicare patients

553

Average age 76

Services billed

2,091

318 women, 235 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Arthritis 43%
Diabetes 34%
Ischemic heart disease 30%
Chronic kidney disease 26%
Osteoporosis 19%
Atrial fibrillation 18%
Depression 17%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 6 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
LUMIGAN
  • AbbVie, Inc. $166
$166 318 —
Rocklatan
  • Alcon Vision LLC $90
$90 78 —
VYZULTA
  • Bausch & Lomb Americas Inc. $55
$55 106 —
IYUZEH
  • Thea Pharma Inc. $44
$44 — —
EYSUVIS
  • Alcon Vision LLC $12
$12 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See all 6 in the dashboard with a free account

Records

155 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Ophthalmology in Texas

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record